| TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells M Bartucci, R Dattilo, C Moriconi, A Pagliuca, M Mottolese, G Federici, ... Oncogene 34 (6), 681-690, 2015 | 375 | 2015 |
| Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer M Musumeci, V Coppola, A Addario, M Patrizii, M Maugeri-Sacca, ... Oncogene 30 (41), 4231-4242, 2011 | 277 | 2011 |
| Cancer stem cells and chemosensitivity M Maugeri-Saccà, P Vigneri, R De Maria Clinical Cancer Research 17 (15), 4942-4947, 2011 | 235 | 2011 |
| DNA damage repair pathways in cancer stem cells M Maugeri-Sacca, M Bartucci, R De Maria Molecular cancer therapeutics 11 (8), 1627-1636, 2012 | 205 | 2012 |
| Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy M Bartucci, S Svensson, P Romania, R Dattilo, M Patrizii, M Signore, ... Cell Death & Differentiation 19 (5), 768-778, 2012 | 200 | 2012 |
| KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden D Marinelli, M Mazzotta, S Scalera, I Terrenato, F Sperati, L D'Ambrosio, ... Annals of Oncology 31 (12), 1746-1754, 2020 | 156 | 2020 |
| The Hippo pathway in normal development and cancer M Maugeri-Saccà, R De Maria Pharmacology & therapeutics 186, 60-72, 2018 | 152 | 2018 |
| Triple positive breast cancer: a distinct subtype? P Vici, L Pizzuti, C Natoli, T Gamucci, L Di Lauro, M Barba, D Sergi, ... Cancer treatment reviews 41 (2), 69-76, 2015 | 147 | 2015 |
| BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial–mesenchymal transition V Coppola, M Musumeci, M Patrizii, A Cannistraci, A Addario, ... Oncogene 32 (14), 1843-1853, 2013 | 117 | 2013 |
| Metabolic features of cancer stem cells: the emerging role of lipid metabolism R Mancini, A Noto, ME Pisanu, C De Vitis, M Maugeri-Saccà, G Ciliberto Oncogene 37 (18), 2367-2378, 2018 | 114 | 2018 |
| Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives E Krasniqi, G Barchiesi, L Pizzuti, M Mazzotta, A Venuti, M Maugeri-Saccà, ... Journal of hematology & oncology 12, 1-26, 2019 | 109 | 2019 |
| Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies P Vici, L Pizzuti, L Mariani, G Zampa, D Santini, L Di Lauro, T Gamucci, ... Expert review of vaccines 15 (10), 1327-1336, 2016 | 106 | 2016 |
| The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications M Maugeri-Saccà, M Barba, L Pizzuti, P Vici, L Di Lauro, R Dattilo, I Vitale, ... Expert reviews in molecular medicine 17, e14, 2015 | 88 | 2015 |
| Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: a systematic review and meta-analysis of phase III randomized clinical … A Grassadonia, I Sperduti, P Vici, L Iezzi, D Brocco, T Gamucci, L Pizzuti, ... Journal of Clinical Medicine 7 (12), 542, 2018 | 87 | 2018 |
| CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells G Manic, M Signore, A Sistigu, G Russo, F Corradi, S Siteni, M Musella, ... Gut 67 (5), 903-917, 2018 | 84 | 2018 |
| Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trials F Sperati, P Vici, M Maugeri-Saccà, S Stranges, N Santesso, L Mariani, ... PloS one 8 (7), e69269, 2013 | 77 | 2013 |
| Emerging biological treatments for uterine cervical carcinoma P Vici, L Mariani, L Pizzuti, D Sergi, L Di Lauro, E Vizza, F Tomao, ... Journal of Cancer 5 (2), 86, 2014 | 75 | 2014 |
| A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience P Vici, L Pizzuti, A Michelotti, I Sperduti, C Natoli, L Mentuccia, L Di Lauro, ... Oncotarget 8 (34), 56921, 2017 | 71 | 2017 |
| Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma ME Pisanu, M Maugeri-Saccà, L Fattore, S Bruschini, C De Vitis, E Tabbì, ... Journal of Experimental & Clinical Cancer Research 37, 1-17, 2018 | 69 | 2018 |
| Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy M Maugeri-Saccà, M Bartucci, R De Maria Cancer treatment reviews 39 (5), 525-533, 2013 | 69 | 2013 |
Matilde TodaroUniversity Researcher, University of PalermoEmail verificata su unipa.it
